AMYLIN PHARMACEUTICALS, INC. Patent applications |
Patent application number | Title | Published |
20130096531 | HYPODERMIC NEEDLE ASSEMBLY HAVING A TRANSITION HUB FOR ENHANCING FLUID DYNAMICS AND MICROSPHERE INJECTABILITY - A hypodermic needle assembly and a method of delivering a microsphere drug. A hypodermic needle assembly includes an injection needle; an injection device; and a hub defining a cavity including a transition portion having a first end and a second end between the first end and an inlet of the injection needle and having a gradually decreasing diameter from the first end to the second end, wherein the hub is coupled between the injection needle and the injection device such that the first end is in fluidic communication with an outlet of the injection device and the second end is in fluidic communication with the inlet of the injection needle, wherein the diameter of the cavity at the first end is larger than an outlet diameter of the injection device, and wherein the diameter at the second end is substantially the same as an inlet diameter of the injection needle. | 04-18-2013 |
20120302501 | TREATMENT OF DIABETIC CARDIOMYOPATHY WITH A GLP-1 PEPTIDE - Hibernating myocardium is characterized by viable myocardium with impaired function due to localized reduced perfusion. Hibernating myocytes retain cellular integrity, but cannot sustain high-energy requirements of contraction. High plasma levels of catecholamines, such as norepinepherine, are believed to be predictive of mortality from hibernating myocardium. Likewise, high levels of catecholamines lead to cardiomyopathy in patients with diabetes. GLP-1 reduces plasma norepinepherine levels, and it thus is useful in a method of treating hibernating myocardium or diabetic cardiomyopathy. | 11-29-2012 |
20120295850 | GLP-1 RECEPTOR AGONISTS TO TREAT PANCREATITIS - The disclosure provides the use of GLP-1 receptor agonist compounds to treat pancreatitis (e.g., acute, chronic, hemorrhagic, necrotizing) in patients. The disclosure also provides the use of GLP-1 receptor agonist compounds to reduce elevated plasma amylase and/or lipase concentrations in patients. An exemplary GLP-1 receptor agonist compound is exenatide. | 11-22-2012 |
20120294855 | GLP-1 RECEPTOR AGONIST COMPOUNDS FOR OBSTRUCTIVE SLEEP APNEA - The disclosure provides, among other things, the use of GLP-1 receptor agonist compounds to treat obstructive sleep apnea. The GLP-1 receptor agonist compounds may be exendins, exendin analogs, GLP-1(7-37), GLP-1 (7-37) analogs (e.g., GLP-1 (7-36)-NH2) and th like. The GLP-1 receptor agonist compound may be exenatide. | 11-22-2012 |
20120253023 | HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES - The present invention relates generally to novel, selectable hybrid polypeptides useful as agents for the treatment and prevention of metabolic diseases and disorders which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, such as diabetes and diabetes-related conditions. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes. | 10-04-2012 |
20120231022 | GLP-1 RECEPTOR AGONIST COMPOUNDS FOR SLEEP ENHANCEMENT - The disclosure provides, among other things, the use of GLP-1 receptor agonist compounds to enhance sleep, increase the duration and/or intensity of non-rapid eye movement (NREM) sleep, treat NREM sleep disorders, and to treat circadian rhythm sleep disorders. The GLP-1 receptor agonist compounds may be exendins, exendin analogs, GLP-1(7-37), GLP-1(7-37) analogs (e.g., GLP-1(7-36)-NH | 09-13-2012 |
20120196799 | Amylin Family Peptides and Methods for Making and Using Them - Methods for treating obesity are disclosed which comprise administration of a therapeutically effective amount of an amylin or an amylin agonist alone or in conjunction with another obesity relief agent. Additionally, methods for reducing insulin-induced weight gain are disclosed which comprise administration of a therapeutically effective amount of an amylin or an amylin agonist. | 08-02-2012 |
20120196796 | AMYLIN FAMILY PEPTIDES AND METHODS FOR MAKING AND USING THEM - The present invention relates to novel compounds having a function of a peptide in the amylin family, related nucleic acids, expression constructs, host cells, and processes production of the compounds. The compounds of the invention include one or more amino acid sequence modifications. In addition, methods and compositions are disclosed to treat and prevent metabolic disorders such as obesity, diabetes, and increased cardiovascular risk. | 08-02-2012 |
20120135922 | MODIFIED EXENDINS AND EXENDIN AGONISTS - Novel modified exendins and exendin agonists having an exendin or exendin agonist linked to one or more polyethylene glycol polymers, for example, and related formulations and dosages and methods of administration thereof are provided. These modified exendins and exendin agonists, compositions and methods are useful in treating diabetes and conditions that would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying or inhibiting food intake. | 05-31-2012 |
20120046222 | N-TERMINUS CONFORMATIONALLY CONSTRAINED GLP-1 RECEPTOR AGONIST COMPOUNDS - The disclosure provides N-terminus conformationally constrained compounds, which may comprise peptide mimetics and/or amino acid substitutions, which may be used in peptides, such as GLP-1 receptor agonist compounds, to induce a β-turn secondary structure at the N-terminus. The N-terminus conformationally constrained compounds may be used for research purposes; to produce GLP-1 receptor agonist compounds having improved GLP-1 receptor binding activity, enzymatic stability, or in vivo glucose lowering activity; and to develop GLP-1 receptor agonist compounds which have fewer amino acid residues. The disclosure also provides GLP-1 receptor agonist compounds, such as exendins, exendin analogs, GLP-1 (7-37), GLP-1 (7-37) analogs, comprising the N-terminus conformationally constrained compounds. The compounds are useful for treating various diseases, such as diabetes and obesity. The disclosure also provides methods for chemically synthesizing the N-terminus conformationally constrained compounds. | 02-23-2012 |
20120004168 | EXENDINS AND EXENDIN AGONIST ANALOGS TO REGULATE GASTROINTESTINAL MOTILITY - Methods for reducing gastric motility and delaying gastric emptying for therapeutic and diagnostic purposes are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist. Methods for treating conditions associated with elevated, inappropriate, or undesired post-prandial blood glucose levels are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist alone or in conjunction with other anti-gastric emptying agents. | 01-05-2012 |
20110306549 | GLP-1 RECEPTOR AGONISTS TO TREAT PANCREATITIS - The disclosure provides the use of GLP-1 receptor agonist compounds to treat pancreatitis (e.g., acute, chronic, hemorrhagic, necrotizing) in patients. The disclosure also provides the use of GLP-1 receptor agonist compounds to reduce elevated plasma amylase and/or lipase concentrations in patients. An exemplary GLP-1 receptor agonist compound is exenatide. | 12-15-2011 |
20110288028 | AMYLIN AND AMYLIN AGONISTS FOR TREATING PSYCHIATRIC DISEASES AND DISORDERS - Methods and compositions for treating psychiatric diseases and disorders are disclosed. The methods provided generally involve the administration of an amylin or an amylin agonist to a subject in order to treat psychiatric diseases and disorders, and conditions associated with psychiatric diseases and disorders. | 11-24-2011 |
20110281798 | Methods for Lowering Plasma Glucagon with Exendins and Exendin Agonist Analogs - Novel formulations containing exendins, exendin agonists and/or exendin analogs are provided. | 11-17-2011 |
20110263491 | COMPOSITIONS AND METHODS FOR THE CONTROL, PREVENTION AND TREATMENT OF OBESITY AND EATING DISORDERS - Compositions and methods for preventing, treating or controlling conditions or disorders associated with obesity, diet and nutrition are provided. The methods provided generally involve the administration of an Amylin or an Amylin agonist to a subject in order to prevent, treat or control conditions or disorders associated with obesity, diet and nutrition. | 10-27-2011 |
20110245162 | METHODS FOR TREATING DIABETES AND REDUCING BODY WEIGHT - Methods for reducing body weight, altering body composition, treating diabetes, reducing HbA | 10-06-2011 |
20110195904 | METHODS OF TREATMENT USING EXENDIN PEPTIDES OR GLP-1 PEPTIDES - Methods for increasing urine flow are disclosed, comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. Methods for increasing urinary sodium excretion and decreasing urinary potassium concentration are also disclosed. The methods are useful for treating conditions or disorders associated with toxic hypervolemia, such as renal failure, congestive heart failure, nephrotic syndrome, cirrhosis, pulmonary edema, and hypertension. The present invention also relates to methods for inducing an inotropic response comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. These methods are useful for treating conditions or disorders that can be alleviated by an increase in cardiac contractility such as congestive heart failure. Pharmaceutical compositions for use in the methods of the invention are also disclosed. | 08-11-2011 |
20110178014 | PREVENTION AND TREATMENT OF CARDIAC ARRHYTHMIAS - Compositions of the invention, including compounds that bind to a receptor for a glucagon-like peptide-1, an incretin, a glucagon-like peptide-1 (GLP-1), an exendin, or an agonist, an analog (preferably an agonist analog), a derivative, or a variant of any of aforementioned compounds, are used in the prevention and treatment of arrhythmias associated with cardiac ischemia, cardiac ischemia-perfusion and/or congestive heart failure. The invention relates to both the method and compositions for such treatment. | 07-21-2011 |
20110136737 | DPP-IV Resistant GIP Hybrid Polypeptides with Selectable Properties - The Present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes. | 06-09-2011 |
20110097751 | GLP-1 RECEPTOR AGONIST BIOASSAYS - Provided herein are cell-based bioassays for measuring GLP-I receptor agonist activity of test compounds, such as GLP-I receptor agonist compounds. Exemplary GLP-I receptor agonist compounds include exendins, exendin analogs, GLP-1(7-37), and GLP-1(7-37) analogs. The bioassays are useful for quantitatively determining cAMP generated in samples containing GLP-I receptor agonist compounds (e.g., exenatide) and 6-23 (clone 6) cells having GLP-I receptors, whereby the amount of cAMP generated can be correlated to the GLP-I receptor agonist activity of the GLP-I receptor agonist compounds (e.g., exenatide). Suitable cell-based bioassays include enzyme-linked immunosorbent assays and homogeneous time-resolved fluorescence assays. | 04-28-2011 |
20110071076 | NOVEL EXENDIN AGONIST COMPOUNDS - Novel exendin agonist compounds are provided. These compounds are useful in treating Type I and II diabetes and conditions which would benefit by lower plasma glucose and delaying and/or slowing gastric emptying. | 03-24-2011 |
20110034377 | Exendin and Exendin Agonists for Eating Disorders - Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed. | 02-10-2011 |
20100323955 | METHODS FOR TREATING OBESITY AND OBESITY RELATED DISEASES AND DISORDERS - Methods for treating obesity or obesity related disorders are disclosed. These methods include the use of anti-obesity agents directed to the forebrain in combination with anti-obesity agents directed to the hindbrain. | 12-23-2010 |
20100298768 | Pen Injection Device and Method of Using Same - Pen injection devices ( | 11-25-2010 |
20100292172 | Peptide-Peptidase Inhibitor Conjugates and Methods of Using Same - Peptide-peptidase inhibitor conjugate molecules are disclosed. These conjugate molecules are useful as agents for the treatment and prevention of metabolic and cardiovascular diseases, disorders, and conditions. Such diseases, conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, and other diabetes-related disorders. | 11-18-2010 |
20100286365 | PEPTIDE-PEPTIDASE-INHIBITOR CONJUGATES AND METHODS OF MAKING AND USING SAME - Peptide-peptidase inhibitor conjugate molecules and methods of manufacture thereof are disclosed. These conjugate molecules are useful as agents for the treatment and prevention of metabolic and cardiovascular diseases, disorders, and conditions. Such diseases, conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, and other diabetes-related disorders. | 11-11-2010 |
20100211042 | Drug Delivery Device - Embodiments of the invention generally provide a device and method for minimizing injection pain and preventing needle clogging during injection of a drug formulation into skin. Generally, the invention provides a device comprising a needle having a point to penetrate skin on one end, a hub having a diameter larger than that of the needle attached to the opposite end of the needle and connectable to a housing defining a chamber for receiving a formulation, and a polymer wrap attached to the hub, wherein the polymer wrap is tapered to the needle so as to pass through skin when the point is inserted into the skin, and wherein a space between the needle and the polymer wrap lies in a flow path of the formulation into the skin, such that formulation is injected through the space between the needle and the polymer wrap. | 08-19-2010 |
20100191182 | Mixing Tool - The present invention provides devices and methods for mixing a formulation containing two or more constituents, such as a drug product and a diluent. The devices have a chamber for securing a container of the drug product. Various embodiments are presented. In one embodiment the device has two or more sides connected by a hinge, the two or more sides defining the chamber between them, and a handle for grasping and manipulating the device. In another embodiment the device has a housing with two or more side bars defining the chamber, the container being visible from outside the housing between the side bars and having a stopping element at the distal end, and a handle having two arms for grasping. | 07-29-2010 |
20100168013 | Neuromedin and FN-38 Peptides for Treating Psychiatric Diseases - Methods and compositions for treating psychiatric diseases and disorders are disclosed. The methods provided generally involve the administration of an NMX peptide, an FNX peptide, or an NMX receptor agonist, or analogs or derivatives thereof, to a subject in order to treat psychiatric diseases and disorders, and conditions associated with psychiatric diseases and disorders. | 07-01-2010 |
20100168011 | Pharmaceutical Formulations and Methods for Making the Same - In certain embodiments, the invention relates to pre-lyophilization formulations, lyophilized compositions, reconstituted formulations, kits comprising the same, and methods for preparing, storing and using the same. | 07-01-2010 |
20100125054 | Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders - Methods and compositions for treating psychiatric diseases and disorders are disclosed. The methods provided generally involve the administration of an amylin or an amylin agonist to a subject in order to treat psychiatric diseases and disorders, and conditions associated with psychiatric diseases and disorders. | 05-20-2010 |
20100099619 | PANCREATIC POLYPEPTIDE FAMILY MOTIFS, POLYPEPTIDES AND METHODS COMPRISING THE SAME - The present invention provides novel Pancreatic Polypeptide Family (“PPF”) polypeptides and methods for their use. | 04-22-2010 |
20100094254 | Formulation Delivery Device - The present invention provides a device for injection of formulations into a patient. In one embodiment the injection is sub-cutaneous. The device is convenient for injecting viscous formulations that would otherwise clog conventional injection devices, for example formulations containing microspheres, suspensions, and other viscous substances. Generally, the device features a needle for piercing the skin, an internal chamber for holding and transmitting fluid, a plunger for applying pressure to the internal chamber, a switch for triggering withdrawal of the needle, a sheath at least partially encompassing the needle and having a flow path within the sheath, and a spring that expands when the switch is triggered, and which thereby at least partially withdraws the needle from the sheath. | 04-15-2010 |
20100029554 | Composition and Methods for Treatment of Congestive Heart Failure - Provided herein is the use of GLP-1 molecules or agonists and analogs thereof, and the use of exendin molecules or agonists and analogs thereof, including their derivatives and active fragments, for the prevention or treatment of congestive heart failure. Pharmaceutical compositions for use in the methods described herein are also disclosed. Further provided are compositions and methods for the treatment and/or prevention of diabetes mellitus, hyperglycemia, insulin resistance and obesity, and for the reduction of food intake and suppression of appetite of subjects. | 02-04-2010 |
20100009907 | Glucagon-Like Peptides and Uses Thereof - The present invention relates to non-mammalian Glucagon-like peptides (nmGLP-1), analogs thereof, related nucleic acids, and processes production of such peptides. The nmGLP-1 peptides and analogs thereof of the invention include one or more amino acid sequence modifications. In addition, methods and compositions are disclosed to treat and prevent obesity, reducing body weight, controlling glycemia, controlling or reducing appetite, and reducing food intake. | 01-14-2010 |
20090312246 | Uses of Glucoregulatory Proteins - The present invention relates generally to the novel use of incretin compounds (ICs) and amylinomimetic compounds to treat, prevent, or ameliorate a variety of metabolic conditions or diseases. | 12-17-2009 |
20090291886 | TRANSMUCOSAL DELIVERY OF PEPTIDES AND PROTEINS - Provided are methods and compositions for enhancing the transmucosal absorption of bioactive peptides and proteins. More particularly, the invention provides compositions for enhancing the transmucosal absorption of bioactive peptides and proteins, such as exendin-4, PYY, PYY | 11-26-2009 |
20090286723 | Hybrid Polypeptides with Selectable Properties - The present invention relates generally to novel, selectable hybrid polypeptides useful as agents for the treatment and prevention of metabolic diseases and disorders which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, such as diabetes and diabetes-related conditions. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes. | 11-19-2009 |
20090247463 | POLYMER-BASED SUSTAINED RELEASE DEVICE - This invention relates to compositions for the sustained release of biologically active polypeptides, and methods of forming and using said compositions, for the sustained release of biologically active polypeptides. The sustained release compositions of this invention comprise a biocompatible polymer having dispersed therein, a biologically active polypeptide and a sugar. | 10-01-2009 |
20090239796 | METHODS FOR TREATING DIABETES AND REDUCING BODY WEIGHT - Methods for reducing body weight, altering body composition, treating diabetes, reducing HbA | 09-24-2009 |
20090215694 | Lyophilized Formulations of Exendins and Exendin Agonist Analogs - Novel formulations containing exendins, exendin agonists and/or exendin analogs are provided. | 08-27-2009 |
20090209460 | COMPOSITIONS AND METHODS FOR TREATING OBESITY AND RELATED METABOLIC DISORDERS - The present invention relates to the use of neuromedins in methods to treat and prevent conditions such as obesity and other food-related disorders. In addition, novel peptides, FNX Peptides, are provided, which find use in treating these disorders. | 08-20-2009 |
20090203603 | Compositions for the Treatment and Prevention of Nephropathy - Compositions and methods for the prevention and treatment of nephropathy, including hypertensive and diabetic nephropathy, and nephropathy associated with insulin resistance and metabolic syndrome are described. Compositions of the invention include a compound that binds to a receptor for the glucagon like peptide-1, an incretin, a glucagon-like peptide-1 (GLP-1), an exendin, or an analog (including an agonist analog), derivative, or variant of any of them. | 08-13-2009 |
20090203597 | Methods to Restore Glycemic Control - Provided herein are methods and compositions to achieve a sustained delay in the progression of, or an amelioration of diabetes in a subject, or a delay in diabetes onset in a subject at risk for diabetes, comprising an abbreviated course of administration of a pharmaceutical composition comprising an exendin or an exendin agonist analog in an amount effective to induce cell regeneration. | 08-13-2009 |
20090186817 | PEPTIDE-PEPTIDASE INHIBITOR CONJUGATES AND METHODS OF USING SAME - Peptide-peptidase inhibitor conjugate molecules are disclosed. These conjugate molecules are useful as agents for the treatment and prevention of metabolic and cardiovascular diseases, disorders, and conditions. Such diseases, conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, and other diabetes-related disorders. | 07-23-2009 |
20090181890 | Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders - Methods and compositions for treating psychiatric diseases and disorders are disclosed. The methods provided generally involve the administration of an amylin or an amylin agonist to a subject in order to treat psychiatric diseases and disorders, and conditions associated with psychiatric diseases and disorders. | 07-16-2009 |
20090176704 | Exendin Agonist Analogs to Treat Diabetes - Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed. | 07-09-2009 |
20090163423 | Exendins and Exendin Agonist Analogs to Regulate Gastrointestinal Motility - Methods for reducing gastric motility and delaying gastric emptying for therapeutic and diagnostic purposes are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist. Methods for treating conditions associated with elevated, inappropriate, or undesired post-prandial blood glucose levels are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist alone or in conjunction with other anti-gastric emptying agents. | 06-25-2009 |
20090156474 | Methods for treating obesity and obesity related diseases and disorders - Methods for treating obesity or obesity related disorders are disclosed. These methods include the use of anti-obesity agents directed to the forebrain in combination with anti-obesity agents directed to the hindbrain. | 06-18-2009 |
20090137466 | Use of GLP-1, Exendin and Agonists Thereof To Delay or Prevent Cardiac Remodeling - The present invention relates generally to the novel use of cardioprotective incretin compounds (CICs) such as GLP-1 and exendin and agonists thereof, including analogs and derivatives to prevent, delay, attenuate, or ameliorate cardiac remodeling. The present invention relates to methods for using CICs for the treatment of conditions associated with cardiac remodeling. The present invention further relates to methods for using CICs for the reduction of the risk or severity of congestive heart failure. | 05-28-2009 |
20090069226 | Transmucosal delivery of peptides and proteins - Provided are methods and compositions for enhancing the transmucosal absorption of bioactive peptides and proteins. More particularly, the invention provides compositions for enhancing the transmucosal absorption of bioactive peptides and proteins, such as exendin-4, PYY, PYY3-36, and GLP-1 and their analogs and derivatives, wherein the compositions comprise an absorption enhancing mixture of a cationic polyamino acid, at least one additional absorption enhancing agent, and a buffer that is compatible with the polyamino acid. Also provided are methods for enhancing the transmucosal absorption and bioavailability of bioactive peptides and proteins using such compositions. | 03-12-2009 |
20090062193 | COMPOSITIONS AND METHODS FOR THE CONTROL, PREVENTION AND TREATMENT OF OBESITY AND EATING DISORDERS - Compositions and methods for preventing, treating or controlling conditions or disorders associated with obesity, diet, and nutrition are provided. The methods provided generally involve the administration of an amylin or an amylin agonist to a subject in order to prevent, treat or controlling conditions or disorders associated with obesity, diet, and nutrition. | 03-05-2009 |
20090054341 | Methods of Treatment Using Exendin Peptides or GLP-1 Peptides - Methods for increasing urine flow are disclosed, comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. Methods for increasing urinary sodium excretion and decreasing urinary potassium concentration are also disclosed. The methods are useful for treating conditions or disorders associated with toxic hypervolemia, such as renal failure, congestive heart failure, nephrotic syndrome, cirrhosis, pulmonary edema, and hypertension. The present invention also relates to methods for inducing an inotropic response comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. These methods are useful for treating conditions or disorders that can be alleviated by an increase in cardiac contractility such as congestive heart failure. Pharmaceutical compositions for use in the methods of the invention are also disclosed. | 02-26-2009 |
20090036364 | GIP ANALOG AND HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES - The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes. | 02-05-2009 |
20090035253 | Poly(lactide-Co-glycolide) based sustained release microcapsules comprising a polypeptide and a sugar - This invention relates to compositions for the sustained release of biologically active polypeptides, and methods of forming and using said compositions, for the sustained release of biologically active polypeptides. The sustained release compositions of this invention comprise a biocompatible polymer having dispersed therein, a biologically active polypeptide and a sugar. | 02-05-2009 |
20090029913 | Novel exendin agonist compounds - Novel exendin agonist compounds are provided. These compounds are useful in treating diabetes and conditions which would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying. | 01-29-2009 |
20090018053 | FORMULATIONS FOR AMYLIN AGONIST PEPTIDES - The present invention is concerned with a pharmaceutical formulation comprising an amylin agonist and optionally a buffer, a tonicifier or stabilizer, and a preservative in a container, for example, a vial, prefilled cartridge, prefilled syringe or disposable pen. This formulation may be in liquid, gel, solid or powdered form for delivery, for example, via nasal, pulmonary, oral, sublingual, buccal, transdermal, or parenteral routes. Formulation with biocompatible polymers and release modifiers, such as sugars, can facilitate controlled release after injection, minimizing the number of administrations to a patient. These formulations maintain stability upon storage under refrigerated or room temperature conditions. Such formulations can be further combined with insulin for administration to a patient. | 01-15-2009 |
20080312157 | GIP ANALOG AND HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES - The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes. | 12-18-2008 |
20080287355 | Amylin and Amylin Agonists For Treating Psychiatric Diseases and Disorders - Methods and compositions for treating psychiatric diseases and disorders are disclosed. The methods provided generally involve the administration of an amylin or an amylin agonist to a subject in order to treat psychiatric diseases and disorders, and conditions associated with psychiatric diseases and disorders. | 11-20-2008 |
20080274952 | Amylin Family Peptides And Methods For Making And Using Them - The present invention relates to obesity related polypeptides (ORPs), related nucleic acids, expression constructs, host cells, and processes production of the obesity related polypeptides. The ORPs of the invention include one or more amino acid sequence modifications. In addition, methods and compositions are disclosed to treat and prevent metabolic disorders such as obesity, diabetes, and increased cardiovascular risk. | 11-06-2008 |
20080249018 | Exendin Analog Formulations - Novel formulations containing exendins, exendin agonists and/or exendin analogs are provided | 10-09-2008 |
20080214467 | Exendins and Exendin Agonists Modified with Albumin - Novel modified exendins and exendin agonists having an exendin or exendin agonist linked to one or more molecular weight increasing compounds, for example, albumin, polyethylene glycol polymers, and related formulations and dosages and methods of administration thereof are provided. These modified exendins and exendin agonists, compositions and methods are useful in treating diabetes and conditions that would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying or inhibiting food intake. | 09-04-2008 |
20080207512 | Methods for Treating Obesity and Obesity Related and Disorders - Methods for treating obesity or obesity related disorders are disclosed. These methods include the use of anti-obesity agents directed to the forebrain in combination with anti-obesity agents directed to the hindbrain. | 08-28-2008 |
20080207501 | Amylin Family Polypeptide-6 (Afp-6) Analogs and Methods of Making and Using Them - The present invention relates to Amylin Family Polypeptide-6 (AFP-6) analogs, which include derivatives and fragments, related nucleic acids, expression constructs, host cells, and processes for recombinant production of the AFP-6 analogs. The AFP-6 analogs of the invention include one or more amino acid sequence modifications. In addition, methods and compositions are disclosed to treat and prevent conditions such as metabolic and cardiovascular disorders, e.g., obesity, diabetes, metabolic syndrome, myocardial ischemia, and increased cardiovascular risk. | 08-28-2008 |
20080200390 | Exendins and Exendin Agonists Modified with Polyamino Acids - Novel modified exendins and exendin agonists having an exendin or exendin agonist linked to one or more molecular weight increasing compounds, for example, polyamino acids, polyethylene glycol polymers, and related formulations and dosages and methods of administration thereof are provided. These modified exendins and exendin agonists, compositions and methods are useful in treating diabetes and conditions that would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying or inhibiting food intake. | 08-21-2008 |
20080200383 | Pharmaceutical Formulations Comprising Incretin Peptide and Aprotic Polar Solvent - The present disclosure is directed to stable pharmaceutical formulations and uses thereof. | 08-21-2008 |